MeSH tree: C15.378.463
Personalized medicine is already a reality in clinical practice, and CAR-T cell therapy is one of its most promising tools. This innovative approach, which involves genetically modifying the cells of the immune system, is ...
May 20, 2025
0
23
An innovative blood cancer treatment regimen could extend remission by seven months on average, according to a clinical trial led by the University of Leeds.
May 15, 2025
0
23
How cancer patients relying on daratumumab feel physically before starting the therapy can predict how long they will live and how well they will respond to the anti-multiple myeloma (MM) drug, according to a new study published ...
May 14, 2025
0
16
For U.S. patients with severe hemophilia A, prophylaxis with efanesoctocog alfa is neither conventionally nor distributionally cost-effective, according to a study published online April 22 in the Annals of Internal Medicine.
Apr 28, 2025
0
11
Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal plasma cells accumulate, they crowd out healthy cells and cause symptoms such as bone pain and tiredness.
Apr 25, 2025
0
20
Annual whole-body, low-dose computed tomography (WBLDCT) can improve the management of smoldering multiple myeloma (SMM), according to a study published online March 25 in the Journal of Clinical Medicine.
Apr 22, 2025
0
11
Researchers at the VIB-UGent Center for Medical Biotechnology have discovered a promising strategy to improve treatment responses in multiple myeloma patients by blocking a protein that plays a key role in drug resistance. ...
Apr 15, 2025
0
16
Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, prognosis, and therapeutic management of multiple myeloma. This new study in The Journal of Molecular ...
Apr 14, 2025
0
21
A new study conducted by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has uncovered a key mechanism behind lenalidomide resistance in multiple myeloma ...
Apr 10, 2025
0
19
The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with ...
Apr 3, 2025
0
19
